The Nanosonics (ASX: NAN) H1 FY 2023 results saw record revenue, improving margins and positive free cash flow.

The H1 FY 2023 Lovisa (ASX: LOV) showed strong profit and revenue growth, but shareholders do take on some risk.

Data#3 (ASX: DTL) presented record results in H1 FY 2023. Can it match this performance in the second half, and is it still cheap?

The H1 FY 2023 Pro Medicus (ASX: PME) Results showed record half year revenue and profit. While the outlook is rosy, cash flow was less ideal.

Your handy ASX small cap reporting schedule, replete with links to results conference call registration and results webinars.